Human leucine-rich repeat containing protein expressed predominately in small intestine, HLRRSI1

Abstract

The present invention provides novel polynucleotides encoding HLRRSI1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRSI1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

1 - 23 . (canceled)  
     
     
         24 . An isolated antibody or fragment thereof that binds to a polypeptide selected from the group consisting of: 
 a.) an isolated polypeptide consisting of amino acids 1 to 625 of SEQ ID NO:2;    b.) an isolated polypeptide consisting of amino acids 2 to 625 of SEQ ID NO:2;    c.) an isolated polypeptide encoded by the SILRRla cDNA clone contained in ATCC Deposit No: PTA-2679; and    d.) an isolated polypeptide encoded by the SILRRlb cDNA clone contained in ATCC Deposit No: PTA-2674.    
     
     
         25 . The isolated antibody or fragment thereof of  claim 24 , wherein said antibody is (a).  
     
     
         26 . The isolated antibody or fragment thereof of  claim 24 , wherein said antibody is (b).  
     
     
         27 . The isolated antibody or fragment thereof of  claim 24 , wherein said antibody is (c).  
     
     
         28 . The isolated antibody or fragment thereof of  claim 24 , wherein said antibody is (d).  
     
     
         29 . The antibody according to  claim 24  which is polyclonal.  
     
     
         30 . The antibody according to  claim 24  which is monoclonal.  
     
     
         31 . The antibody according to  claim 24  which is chimeric.  
     
     
         32 . The antibody according to  claim 24  which is humanized.  
     
     
         33 . The antibody according to  claim 24  which is mammalian.  
     
     
         34 . The antibody according to  claim 24  which is human.  
     
     
         35 . A hybridoma cell which produces the antibody according to  claim 30 .  
     
     
         36 . The antibody of  claim 24 , wherein the fragment is selected from the group consisting of a) a Fab fragment; b) a F(ab′) 2 fragment, and c) a Fv fragment.  
     
     
         37 . The antibody of  claim 24  which is labeled.  
     
     
         38 . The antibody of  claim 37 , wherein the label is selected from the group consisting of: a) an enzyme; b) a fluorescent label; and c) a radioisotope.  
     
     
         39 . The antibody of  claim 37 , which specifically binds to said polypeptide in an ELISA.  
     
     
         40 . The antibody of  claim 37 , which specifically binds to said polypeptide in a competitive-binding assay.  
     
     
         41 . The antibody of  claim 37 , which specifically binds to said polypeptide in a radioimmunoassay.  
     
     
         42 . The antibody of  claim 37 , which specifically binds to said polypeptide in a FACS.  
     
     
         43 . A kit for detecting a polypeptide consisting of a sequence provided as SEQ ID NO:2 comprising: 
 a) the isolated antibody of  claim 24;  and    b) at least one component to detect binding of the isolated antibody to said polypeptide sequence.    
     
     
         44 . An isolated antibody obtained from an animal that has been immunized with either an isolated polypeptide encoded by the SILRRla cDNA clone contained in ATCC Deposit No: PTA-2679 or an isolated polypeptide encoded by the SILRRlb cDNA clone contained in ATCC Deposit No: PTA-2674., wherein said antibody binds to an antigenic epitope-bearing polypeptide fragment consisting of at least 5 contiguous amino acids of said polypeptide.